Alimta

... New Drugs Lift Eli Lilly QUOTES & SEARCH Quotes Search Site Advanced Search MY STOCKWATCH Select your StockWatch HOT NEWS Analyst ActionsLatest Stories NEWS AND ANALYSIS Tech StocksMarkets ETFs Small Business CommentaryPersonal FinanceThe Good LifeCompany NewsOptions and Futures FEATURED OFFERS Free MembershipAction Alerts PLUSStocks Under $10The Short AdvisorDividend Stock AdvisorThe Trading ReportsCramer RadioCramer's BooksTheStreet.com Value InvestorTelecom ConnectionDaily Swing TradeThe Tech EdgeChartman's Top StocksRealMoney Free TrialBrokersInstitutions CUSTOMER SERVICE Account InfoPasswordLogoutRSS ABOUT US LettersInvestor RelationsCorrections RESEARCH/TOOLS Earnings ReportsMutual Fund FinderStreaming QuotesEconomic CalendarInternet Index Stock News : Robert Steyer New Drugs Lift Eli Lilly By Robert SteyerTheStreet.com Staff Reporter 1/26/2005 11:17 AM EST Click here for more stories by Robert Steyer Updated from 8:15 a.m.

EST Eli Lilly (LLY:NYSE - news - research) Wednesday posted solidly higher fourth-quarter net income, excluding a big one-time tax charge and restructuring costs, as it edged past analysts' EPS estimates thanks to its latest generation of drugs.

Excluding items, net income rose 13% to $814.3 million, or 75 cents a share, vs.

$723.3 million, or 67 cents a share, a year ago.

Analysts were expecting 74 cents a share, according to Thomson First Call.

The news was good enough to send the stock up $1.95, or 3.6%, to $56.80.

Including one-time ...

Read more...